At the Forefront of Immunotherapy

OTCQB: TPIV

1551 Eastlake Ave ESuite 100

Seattle, WA

www.TapImmune.com

CAUTIONARY STATEMENT REGARDING FORWARD LOOKING STATEMENTS

Certain statements contained herein are forward-looking statements within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements in this document include, but are not limited to, statements relating to long-term stability, the Company's plan of operations and finances, the potential for the Company's vaccines and proposed clinical trials.

The reader is cautioned that any such forward-looking statements are not guarantees of future performance and that actual results may differ materially from estimates in the forward-looking statements. The Company undertakes no obligation to revise these forward-looking statements to reflect events or circumstances after the date hereof.

Corporate PresentationJuly 2012TAPIMMUNE

A New Frontier in Immunotherapy

TapImmune is an Immunotherapy

company specializing in the development of

the most comprehensive and

innovative immunotherapeutics

in cancer and infectious diseases.

Corporate PresentationJuly 2012OPPORTUNITY

Why invest in TapImmune now?

Unique and Broad product opportunities in cancer & infectious disease

Two Phase I Clinical Trials ready to progress to Phase II

HER2/neu breast cancer vaccine potential blockbuster

Ovarian Cancer Urgently Needed Therapeutic with blockbuster potential

HUGE market opportunities in multiple therapeutic indications

PolyStart™ expression vector is a significant advance in vaccine

technologies

Strong management & advisory team

Leverage of key collaborations with leading institutions

Series of preclinical and clinical value inflexion points

Significantly undervalued and poised for significant growth

An approach with the potential to change lives and excellent entry level valuation

Corporate PresentationJuly 2012

Leading Immunotherapy Approach:

CANCER• Making tumors visible to T-cells• Stimulating T-killer cells AND T-helper

cells• Applicable to broad patient

populations

INFECTIOUS DISEASE• Up-regulation of Antigen Presentation• Stimulating T-killer cells & T-helper

cells• Applicable Multiple Infectious

Diseases and Biothreats

TAPIMMUNEHarnessing the Power of Immune System

Corporate PresentationJuly 2012The Immune System

The body’s immune system is designed to fight cancer & viral infections Cancers evade the immune system allowing tumor growth

PROBLEM: cancer evades the immune system and current approaches do not address ALL the reasons adequately

Reasons: The Cancer Markers (antigens) are NOT

presented to the Immune System Low or Absent T A P (Antigen Transporter) Epitopes are NOT Naturally Processed (NPE)

T cell response is SHORT lived (No Helper Cells

CD4)

T cell response is NOT a KILLER cell response

(CD8)

Corporate PresentationJuly 2012 The Immunotherapy Space

New Frontier in Treatment of Cancer

PROBLEM: To Stimulate the Immunse System to Effectively KILL Tumors

Traditional ApproachesChemotherapy, Radiation, Surgery, Small Molecules

New ImmunotherapiesImmune Checkpoint Blockade (BMS; Merck)

Monoclonal antibodies (Roche)

T-Cell TherapiesEx-Vivo: Adoptive T-cell transfer (LBIO;Juno)

Dendritic cell transfer (NWBIO;DNDN; PBMD)

In Vivo: Antigen stimulation (ONTY;GALE;IMUC)

BOTH Antigen presentation & T Cell stimulation (TPIV)

Corporate PresentationJuly 2012 The TapImmune Approach

Prime BOTH sides of the tumor Killing equation Proprietary peptide antigens used to stimulate a broad based • T - Helper cell response (CD4) LONG-LIVED • KILLER T-cells to actually KILL the tumor

(CD8)These Proprietary Antigens allow us to treat:• Wider patient populations• Multiple Indications• Multiple Therapeutic Areas (Cancer and

Infectious Disease)

SOLUTION: most COMPREHENSIVE immunotherapeutic in development

Corporate PresentationJuly 2012Product Pipeline

Product Indication Preclinical Phase I Phase II

TPIV100 Class II antigens Her2/neu breast

cancer

TPIV110Class I + II antigens

Her2/neu breast cancer

TPIV200Folate Receptor AlphaQ2 2014

Ovarian/breast cancer

TPIV120 (PolyStart™ Class I/II antigens)

Her2/neu breast cancer

TPIV 300(Class I antigens)

Smallpox

Emerging viral threats

Corporate PresentationJuly 2012

HER2/neu positive breast cancer is one of most aggressive forms

HER2/neu is overexpressed in ~ 30% breast cancer patients (total 220,000 /yr)

Roche’s monoclonal antibody, Herceptin (current standard of care) can only treat ~ 20% of these patients (+$6 billion sales in 2013)

Herceptin does not stimulate Killer T-cells – it slows/retards tumor growth

In Contrast: We believe TapImmune’s comprehensive combination of Killers and Helpers has the potential to provide Long Lasting Immune Response in upto 84% of the HER2/neu positive patient population.

A $ Multi-Billion product potential meeting an UNSATISFIED CLINICAL NEED in a very LARGE Market

Lead Clinical Programs Trial 1: Her2neu Breast Cancer - Mayo Clinic Rochester MN

Herceptin Facts:

Late Stage Survival improved by 4.5 Months.

Early stage treatment resulted in a 9.5% improvement on recurrence.

70% of Her2neu+ patients do NOT respond to treatment

Corporate PresentationJuly 2012HER2/neu Clinical Status

Her2neu Breast Cancer - Mayo Clinic Rochester MN

Phase l

Phase lb/ll

Class II antigens (4 epitopes NPE) discovered in breast cancer patients - Clin. Cancer Res. (2010) 16, 825-83• 22 Patients post Herceptin• 6 x monthly intradermal + GMCSF Interim safety checkpoint completed Positive Immune responses on first 6 patients

(interim data)Excellent Results – Support progression to Phase ll Class II + Class I (p373-382) antigens (4+1)To start Q4, 2014Small safety study100-150 patient multicenter phase II

Corporate PresentationJuly 2012 HER2/neu Clinical Program

Her2neu Breast Cancer - Mayo Clinic Rochester MN

Peptide Antigens to stimulate BOTH:

• T-helper cells – Long Lasting • Antigens discovered in breast cancer

patients• Naturally Processed Epitopes (NPE’s)

• Killer T-cells (p373-382) - Kills Tumor Cells

Leading HER2/neu Vaccine Candidate

Compared to NeuVax by Galena:

4-5x greater KILLING activity against human tumor cell targets

See: J.Immonol. (2013) 190, 479-488

SOLUTION: most COMPREHENSIVE immunotherapeutic in development

Corporate PresentationJuly 2012

Folate Receptor Alpha is expressed over 95% of ovarian cancers, for which the only treatment options are surgery and chemotherapy

Very important and urgent clinical need for a new therapeutic.

Time to recurrence is relatively short for this type of cancer and survival prognosis is extremely poor after recurrence.

US alone, approximately 30,000 ovarian cancer patients newly diagnosed every year. Phase llb/2 advancement expected in late 2014.

Orphan Drug Application – Pending FDA

Another $ Multi-Billion product potential with an UNSATISFIED CLINICAL NEED

Lead Clinical Programs Trial 2: Stage II/II Ovarian & Breast Cancer - Mayo Clinic

URGEN CLINCAL NEED - LARGE MARKET OPPORTUNITY

Corporate PresentationJuly 2012 Ovarian Trial Clinical Status

T Trial 2: Ovarian & Breast Cancer (Folate Alpha) - Mayo Clinic Rochester MN

Phase l

Phase ll Expected to Start in 2014 with Orphan Drug Application - FDA Pending

Antigens Applicable to Ovarian and Triple Negative Breast Cancer

22 patients with Stage II-III Breast, Ovarian, Peritoneal, Fallopian Tube Cancer

Interim safety checkpoint completed Positive Immune responses observedPromising Interim Results – Support progression to Phase ll

Licensing of Phase I

program

Restructure

StartPhase Ib/II

HER2/neu+

breast cancer

PolyStart IP

Folate AlphaBreast/Ovarian

PolyStart™

Finish Preclinical

FDA meetingViral Disease Smallpox Partnership

Start Phase II

TapImmune: 2014 Upcoming Milestones

Q1 Q2 Q3 Q4

NASDAQ

Multiple Inflection Points and Value Drivers

Corporate

Trial 1: Breast Cancer

Trial 2: Ovarian Cancer

Pre-Clinical

Bio-Threat

Corporate PresentationJuly 2012

COLLABORATORS & ADVISORSWorld Class Team

Dr Keith Knutson (Vaccine & Gene Therapy Institute of Florida/Mayo Clinic): Director, Cancer Immunology and Immunotherapy Program, VGTI; Adjunct Faculty - Immunology, Mayo Clinic

Dr Greg Poland: (Mayo Clinic) Head of Vaccines; Infectious disease/biodefense

Dr Mac Cheever (Fred Hutchinson Cancer Research Center) Director Solid Tumor Research; Professor of Medicine/Oncology at the University of Washington (Seattle) & Director of the NCI-funded Cancer Immunotherapy Trials Network (CITN)

Mark Reddish Advisor: Development , BoardProduct Development: Cancer vaccines and Biodefense:Biomira, ID Biomedical, Baxter, Bayer AG

Denis Corin Corporate Finance

Corporate PresentationJuly 2012Management and Advisors

Mark ReddishAdvisor: Development, Board 25 years experience in cancer vaccines and biodefense Biomira, ID Biomedical, Baxter, Bayer AG

Denis CorinCorporate FinanceBeckman, Novartis

Glynn Wilson, PhDCEO25 years experience in product & corporate developmentSmithKline Beecham, Ciba-Geigy, Tacora

Bob Florkiewicz, PhDHead of Research25 years experience, academic and biotechSynergen, TSRI, UW, GSK, Seed IP Law Group

Corporate PresentationJuly 2012

CAP STRUCTURE and COMPSReorganized Feb 2014

TPIV - TAPIMMUNE INCCapital Structure Post Restructure

Shares Outstanding 16,000,000 Public Float 2,000,000 Debt Elimination ~$5,000,000 Market cap ~$30,000,000 Stock Price $2.00

Comparrisons in Immunotherapy and Biotech

Shares Out Market Cap Stock Price GALE (Galena) 105,240,000

$ 250,000,000 $2.50LBIO (Lion Bio) 26,000,000 $ 180,000,000 $6.50INO (Inovio) 240,150,000 $ 565,550,000 $2.39DNDN (Dendreon) 157,490,000 $ 453,560,000 $2.88NWBO (Nothwest Bio) 53,400,000 $ 317,730,000

$5.99

Corporate PresentationJuly 2012OPPORTUNITY

Why invest in TapImmune now?

Unique and Broad product opportunities in cancer & infectious disease

Two Phase I Clinical Trials ready to progress to Phase II

HER2/neu breast cancer vaccine potential blockbuster

Ovarian Cancer Urgently Needed Therapeutic with blockbuster potential

HUGE market opportunities in multiple therapeutic indications

PolyStart™ expression vector is a significant advance in vaccine

technologies

Strong management & advisory team

Leverage of key collaborations with leading institutions

Series of preclinical and clinical value inflexion points

Significantly undervalued and poised for significant growth

An approach with the potential to change lives and excellent entry level valuation

CONTACTGlynn Wilson

Chief Executive Officergwilson@tapimmune.com

Denis CorinCorporate Finance

dcorin@tapimmune.com